Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Slides:

Advertisements

Similar presentations

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.

Advertisements

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

The REAL-CAD Study in 13,054 Patients

The Latest Lipid Guidelines:

Updates and Perspectives in Diabetic Dyslipidemia

Statin Selection in the Elderly

Optimizing Statin Therapy

An Endocrinology Clinic in Dyslipidemia

Statin Selection Aimed to Reduce New-Onset DM Risk:

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Obesity and Dyslipidemia: How Would You Treat?

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statins and the Elderly Patient

Statin Selection in Special Patient Populations: A Case Challenge

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

TNT Study: Baseline Characteristics of the Patients

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Statin Class in Session

Diabetes Increases Risk of CVD

Assessing the State of Statin Therapy

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

Statins and Glucose Metabolism: Are All Agents Alike?

Statin Class in Session

PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins

Personalizing Statin Therapy in Patients With HIV

A Journal Club on Lipid Management:

PCSK9 Inhibitors and Cardiovascular Outcomes

Statins and HIV:.

New LDL-C Lipid Targets

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Lipid Clinic Challenge

Aspirin and Cardioprevention in 2018

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Ezetimibe/simvastatin

Statins, Obesity, and Hyperlipidemia

Glucose Management and Statin Therapy

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Approximate Dose Equivalency of Statin LDL-C Efficacy.

LRC-CPPT and MRFIT Content Points:

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Reducing Risk for CV Outcomes

DECLARE-TIMI 58.

New Lipid-Lowering Guidelines

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Statins and Glucose Metabolism: An Endocrinology Perspective

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Glucose Management and Statin Therapy

Updates on Dyslipidemia

Statin Selection in Patients With Pre-Diabetes: Case Considerations

What's New in Oral Combination Therapy for Type 2 Diabetes?

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Presentation transcript:

The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD

Goals

Multiple Challenges in Statin Selection

Late-Breaking Clinical Trial Session at AHA 2017

REAL-CAD

Primary Endpoint (CV Death/MI/Ischemic Stroke/UA)

Secondary Composite Endpoint Primary Endpoint + Coronary Revascularization*

Additional Secondary Endpoints

Serial Changes in Lipid Parameters and hs-CRP

Safety Outcomes

Lower LDL-C Is Better: Is It Worth It?

Yes, It’s Worth It Further Proof That Lower Is Better

Recommendations for Lipid-Lowering Therapy in Patients With Established CAD

IMPROVE-IT: Benefit With Ezetimibe

J-PREDICT Primary Outcome: Cumulative Incidence of Diabetes

No Signal for T2D With Either 1- or 4-mg Dose of Pitavastatin

REAL-CAD: Application to Other Populations

Team: Nurses, Pharmacists, Nutritionists

Take-Home Pearls/Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)